$2.6 Billion is the total value of Camber Capital Management LP's 33 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GHDX | GENOMIC HEALTH INC | $123,888,000 | +61.1% | 2,458,100 | 0.0% | 4.77% | +26.2% | |
| MDCO | MEDICINES CO | $73,400,000 | +11.4% | 2,000,000 | 0.0% | 2.82% | -12.7% | |
| NUVA | NUVASIVE INC | $62,544,000 | -0.2% | 1,200,000 | 0.0% | 2.41% | -21.8% | |
| BKD | BROOKDALE SENIOR LIVING | $59,085,000 | +35.5% | 6,500,000 | 0.0% | 2.27% | +6.2% | |
| MYGN | MYRIAD GENETICS INC | $56,055,000 | +26.5% | 1,500,000 | 0.0% | 2.16% | -0.9% | |
| ELGX | ENDOLOGIX INC | $52,638,000 | +33.8% | 9,300,000 | 0.0% | 2.02% | +4.9% | |
| AMAG | AMAG PHARMACEUTICALS INC | $51,675,000 | -3.2% | 2,650,000 | 0.0% | 1.99% | -24.2% | |
| ENDP | ENDO INTL PLC | $23,575,000 | +58.8% | 2,500,000 | 0.0% | 0.91% | +24.4% | |
| SGRY | SURGERY PARTNERS INC | $2,013,000 | -13.1% | 135,084 | 0.0% | 0.08% | -32.5% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.